{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+2+-+Placebo&page=27",
    "query": {
      "intervention": "Intervention 2 - Placebo",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1494,
    "total_pages": 150,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+2+-+Placebo&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+2+-+Placebo&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T03:05:09.192Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00890149",
      "title": "Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Abuse",
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BASICS Plus",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "18 Years to 25 Years"
      },
      "enrollment_count": 74,
      "start_date": "2015-09",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "Columbia, Maryland",
      "locations": [
        {
          "city": "Columbia",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890149"
    },
    {
      "nct_id": "NCT05027048",
      "title": "Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Atony",
        "Uterine Atony With Hemorrhage",
        "Postpartum Hemorrhage",
        "Cesarean Section Complications"
      ],
      "interventions": [
        {
          "name": "Calcium chloride",
          "type": "DRUG"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2022-04-04",
      "completion_date": "2023-04-03",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "Pacifica, California",
      "locations": [
        {
          "city": "Pacifica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05027048"
    },
    {
      "nct_id": "NCT02572973",
      "title": "Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Separation Anxiety Disorder",
        "Generalized Anxiety Disorder",
        "Social Phobia"
      ],
      "interventions": [
        {
          "name": "Acoustic Neuromodulation (ANM)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 6,
      "start_date": "2014-07",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2019-01-14",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02572973"
    },
    {
      "nct_id": "NCT06641596",
      "title": "Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight",
        "Metabolic Syndrome X"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Cr-400",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Cr-800",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "PE-500",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "PE-1000",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Kerry Group P.L.C",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 112,
      "start_date": "2019-02-01",
      "completion_date": "2024-05-29",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06641596"
    },
    {
      "nct_id": "NCT01810380",
      "title": "Brexpiprazole in Patients With Acute Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine extended release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 468,
      "start_date": "2013-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "Escondido, California",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01810380"
    },
    {
      "nct_id": "NCT05087342",
      "title": "Latino Semaglutide Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Obesity; Drug",
        "Overweight or Obesity",
        "Weight Loss",
        "Weight Loss Trajectory",
        "Weight, Body"
      ],
      "interventions": [
        {
          "name": "Semaglutide 2.4mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 119,
      "start_date": "2022-12-13",
      "completion_date": "2024-05-29",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05087342"
    },
    {
      "nct_id": "NCT06191094",
      "title": "Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Vitreous Hemorrhage Due to Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Faricimab Injection",
          "type": "DRUG"
        },
        {
          "name": "sham treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-07-12",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06191094"
    },
    {
      "nct_id": "NCT03255629",
      "title": "Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Post-bariatric Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "glucagon",
          "type": "DRUG"
        },
        {
          "name": "Closed loop glucagon pump",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Joslin Diabetes Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-09-19",
      "completion_date": "2018-08-22",
      "has_results": true,
      "last_update_posted_date": "2022-09-06",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03255629"
    },
    {
      "nct_id": "NCT03924856",
      "title": "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 907,
      "start_date": "2019-06-13",
      "completion_date": "2026-05-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 24,
      "location_summary": "La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03924856"
    },
    {
      "nct_id": "NCT01871350",
      "title": "Nutrition Intervention During Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer Patients Receiving Chemotherapy or Chemoradiotherapy"
      ],
      "interventions": [
        {
          "name": "Daily intake for 10 weeks (+/- 2 weeks)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2013-04-26",
      "completion_date": "2015-11-03",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-11-16T03:05:09.192Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01871350"
    }
  ]
}